Fate Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Se prevé que los beneficios de Fate Therapeutics disminuyan en un 6.2% al año, mientras que se espera que sus ingresos anuales crezcan en un 34.3% al año. Se prevé que el BPA crezca en un 3% por año. Se espera que la rentabilidad financiera sea de -74.8% en 3 años.
Información clave
-6.2%
Tasa de crecimiento de los beneficios
3.0%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 24.7% |
Tasa de crecimiento de los ingresos | 34.3% |
Rentabilidad financiera futura | -74.8% |
Cobertura de analistas | Good |
Última actualización | 17 Jun 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01Fate Therapeutics: Data Playing Catchup With Valuation
Dec 06Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 5 | -250 | -167 | -103 | 5 |
12/31/2025 | 5 | -222 | -173 | -174 | 15 |
12/31/2024 | 6 | -201 | -126 | -147 | 15 |
3/31/2024 | 6 | -190 | -140 | -137 | N/A |
12/31/2023 | 64 | -161 | -138 | -132 | N/A |
9/30/2023 | 106 | -173 | -184 | -171 | N/A |
6/30/2023 | 119 | -212 | -209 | -188 | N/A |
3/31/2023 | 137 | -235 | -241 | -212 | N/A |
12/31/2022 | 96 | -282 | -284 | -248 | N/A |
9/30/2022 | 69 | -294 | -290 | -243 | N/A |
6/30/2022 | 68 | -254 | -275 | -221 | N/A |
3/31/2022 | 63 | -233 | -257 | -200 | N/A |
12/31/2021 | 56 | -212 | -214 | -163 | N/A |
9/30/2021 | 55 | -197 | -148 | -113 | N/A |
6/30/2021 | 48 | -212 | -131 | -111 | N/A |
3/31/2021 | 40 | -185 | -47 | -40 | N/A |
12/31/2020 | 31 | -173 | -44 | -39 | N/A |
9/30/2020 | 18 | -149 | -49 | -44 | N/A |
6/30/2020 | 13 | -117 | -39 | -33 | N/A |
3/31/2020 | 11 | -112 | -99 | -92 | N/A |
12/31/2019 | 11 | -98 | -91 | -83 | N/A |
9/30/2019 | 10 | -86 | -75 | -69 | N/A |
6/30/2019 | 8 | -76 | -58 | -52 | N/A |
3/31/2019 | 6 | -72 | -47 | -44 | N/A |
12/31/2018 | 5 | -67 | -41 | -39 | N/A |
9/30/2018 | 4 | -63 | -40 | -38 | N/A |
6/30/2018 | 4 | -57 | -46 | -45 | N/A |
3/31/2018 | 4 | -47 | -44 | -42 | N/A |
12/31/2017 | 4 | -43 | N/A | -37 | N/A |
9/30/2017 | 4 | -38 | N/A | -34 | N/A |
6/30/2017 | 4 | -36 | N/A | -31 | N/A |
3/31/2017 | 4 | -35 | N/A | -30 | N/A |
12/31/2016 | 4 | -33 | N/A | -30 | N/A |
9/30/2016 | 4 | -33 | N/A | -29 | N/A |
6/30/2016 | 4 | -31 | N/A | -29 | N/A |
3/31/2016 | 4 | -30 | N/A | -19 | N/A |
12/31/2015 | 2 | -30 | N/A | -18 | N/A |
9/30/2015 | 1 | -29 | N/A | -18 | N/A |
6/30/2015 | 0 | -28 | N/A | -16 | N/A |
3/31/2015 | N/A | -27 | N/A | -24 | N/A |
12/31/2014 | N/A | -26 | N/A | -22 | N/A |
9/30/2014 | N/A | -25 | N/A | -21 | N/A |
6/30/2014 | 0 | -25 | N/A | -19 | N/A |
3/31/2014 | 0 | -24 | N/A | -17 | N/A |
12/31/2013 | 1 | -21 | N/A | -15 | N/A |
9/30/2013 | 2 | -19 | N/A | -14 | N/A |
6/30/2013 | 2 | -17 | N/A | -13 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que FATE siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que FATE siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que FATE siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (34.3% al año) de FATE crezcan más rápidamente que los del mercado US (8.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (34.3% al año) de FATE crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: FATE se prevé que no sea rentable en 3 años.